Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice

References

• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among psoriasis patients treated with ixekizumab or adalimumab. Patient Prefer Adher. 2020;14:517–527.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Wang S, Shin DB, et al. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. J Am Acad Dermatol. 2014;71(6):1167–1175.
   PubMed Web of Science ®Google Scholar
• Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495–501.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–657.
   PubMed Web of Science ®Google Scholar
• AbbVie. Concomitant longitudinal evaluation of adalimumab with methotrexate in the real world: the CLEAR Study [Internet]. Bethesda (MD): National Library of Medicine; 2018 [cited 2020 October 11]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02196701.
   Google Scholar
• Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol. 2014;15(6):467–478.
   PubMed Web of Science ®Google Scholar
• Belzunegui J, Intxausti JJ, De Dios JR, et al. Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Experimental Rheumatol. 2001;19(6):727–730.
   PubMed Web of Science ®Google Scholar
• Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol. 2007;157(1):213.
   PubMed Web of Science ®Google Scholar
• Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50(5):1370–1382.
   PubMed Web of Science ®Google Scholar
• MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol. 2005;152(3):405–408.
   PubMed Web of Science ®Google Scholar
• Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486.
   PubMed Web of Science ®Google Scholar
• Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46–54.
   PubMedGoogle Scholar
• Opmeer BC, Heydendael VM, De Borgie CA, et al. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol. 2004;140(6):685–690.
   PubMedGoogle Scholar
• FDA [Internet]. FDA approves new psoriasis drug Taltz. Silver Spring (MD): U.S. Food & Drug Administration; 2016 [cited 2017 November 15]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm
   Google Scholar
• Lilly E. TALTZ-ixekizumab injection, solution [Internet]. Indianapolis (IN): Eli Lilly and Company; 2017 [cited 2017 November 15]. Available from: http://uspl.lilly.com/taltz/taltz.html#pi
   Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Cornic L, Levin LA, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33(2):355–366.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Academy Dermatol. 2020;82(4):927–935.
   PubMed Web of Science ®Google Scholar
• ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17(2):200–208.
   PubMed Web of Science ®Google Scholar
• Secretary HHSOof the, (OCR) Ofor CR. HIPAA for Professionals [Internet]. HHS.gov. US Department of Health and Human Services; 2021 [cited 2021 July 13]. Available from: https://www.hhs.gov/hipaa/for-professionals/index.html.
   Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(2):ii65–ii68.
   PubMedGoogle Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Anderson A, Casso D, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatol Treat. 2019;30(2):141–149.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Iskandar IY, Warren RB, Lunt M, et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138(4):775–784.
   PubMed Web of Science ®Google Scholar
• A. Foster S, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. JMCP. 2016;22(4):396–405.
   PubMedGoogle Scholar
• Menter A, Papp K, Gooderham M, et al. Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Leonardi CT, Setayeshgar S, Wang S, et al., editors. Long-term treatment effects of ixekizumab among psoriasis patients who achieved early high level treatment outcomes in a real-world setting: results from a single US dermatology referral practice. Cleveland (OH): American Academy of Dermatology; 2020.
   Google Scholar
• Kamili QU, Miner A, Hapa A, et al. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. J Drugs Dermatol. 2011;10(5):539–544.
   PubMed Web of Science ®Google Scholar
• van den Reek JM, van Lümig PP, Kievit W, et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat. 2013;24(5):361–368.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
   PubMed Web of Science ®Google Scholar